What changed in United Therapeutics Corporation's latest annual report
In the year ended 31 Dec 2025, United Therapeutics Corporation's revenue rose 10.6% to USD 3.18bn, from USD 2.88bn; net income rose 11.7% to USD 1.33bn, from USD 1.20bn; total liabilities fell 14.8% to USD 783.80m, from USD 920.00m.
Year ended 31 Dec 2025. Source: 10-K filed 25 Feb 2026, read it on SEC EDGAR.
USD 2.88bn to USD 3.18bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 2.88bn | 3.18bn | Up 10.6% |
| Net income | 1.20bn | 1.33bn | Up 11.7% |
| Total assets | 7.36bn | 7.88bn | Up 7% |
| Total liabilities | 920.00m | 783.80m | Down 14.8% |
| Cash and cash equivalents | 1.70bn | 1.56bn | Down 8.3% |
| Shareholders' equity | 6.44bn | 7.10bn | Up 10.1% |
Questions people ask
Did United Therapeutics Corporation's revenue grow last year?
Revenue grew 10.6%, from USD 2.88bn to USD 3.18bn in the year ended 31 Dec 2025.
Is United Therapeutics Corporation profitable?
Yes. Net income was USD 1.33bn in the year ended 31 Dec 2025. The year before: USD 1.20bn.
How much cash and debt does United Therapeutics Corporation have?
At its latest year end (31 Dec 2025), United Therapeutics Corporation reported cash and cash equivalents of USD 1.56bn.
Where do these numbers come from?
From United Therapeutics Corporation's own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with United Therapeutics Corporation?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Pharmaceutical Preparations companies
- Eli Lilly And CompanyCash and cash equivalents up 122.4%
- Johnson & JohnsonNet income up 90.6%
- AbbVie Inc.Revenue up 8.6%
- Merck & Co., Inc.Long-term debt up 35.7%
- Abbott LaboratoriesNet income down 51.3%
- Pfizer IncCash and cash equivalents up 9.5%
- Vertex Pharmaceuticals Inc / MaTotal liabilities up 13.9%
- Bristol-Myers Squibb CompanyShareholders' equity up 13.1%